marked.bio

PI3K/mTOR inhibitor · small molecule

gedatolisib

1 active trials across 5 of our biomarkers, targeting PI3K/mTOR. Not approved for any biomarker on marked.bio yet.

Also known as PF-05212384, PKI-587.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 1 1 Phase 1/2
BRAF V600E 0 1 –
KRAS G12C 0 1 –
KRAS G12D 0 1 –
PIK3CA activating mutation 0 2 –

Trials

1 of 4 trials shown

  1. Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

    Active, not recruiting Phase 1/2 Kari Wisinski Started 2019Primary completion 2024-07 NCT03911973

    gedatolisibtalazoparib FDA EU

    Phase II Cohort B \[CLOSED\]: Patients with advanced HER2 negative breast cancer and a germline BRCA1 or 2 (1/2) mutation

    BRCA1/2 mutationStatus may be outdated, last updated 2024-06-07TNBC - Triple-Negative Breast Cancer